Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies
Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with Novo Nordisk A/S (NYSE:NVO) to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity.
Under the terms of the agreement, Deep Apple will discover and optimize compounds using its proprietary drug discovery platform, which combines machine-learning-powered virtual screening with structural biology enabled by cryo-electron microscopy (cryo-EM) to dramatically improve speed, quality, and novelty in lead generation and optimization.
Novo Nordisk will receive exclusive global rights to develop, manufacture, and commercialize the resulting compounds and products in all indications.Both companies will collaborate on the research plan, with program handoff to Novo Nordisk occurring immediately before the start of IND-enabling studies.
Deep Apple is eligible to receive an upfront payment, research costs, and milestone payments from Novo Nordisk.
Deep Apple will be eligible to receive up to $812 million in payments and potential royalties on sales of any products that emerge from the collaboration.
Recently, the Danish pharma giant initiated a Phase 3 trial to evaluate the efficacy and safety of cagrilintide sc combined with semaglutide sc (CagriSema sc) once weekly for weight management and long-term weight maintenance in obese participants.
The two-part study in around 600 participants will last about 3 years and 3 months.
In March, Novo Nordisk announced headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program.
REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema compared to placebo.
After 68 weeks, 61.9% of patients treated with CagriSema were on the highest dose.
When evaluating treatment effects, if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 15.7% after 68 weeks compared to 3.1% with placebo.
Last week, Regeneron Pharmaceuticals, Inc.(NASDAQ:REGN) released interim results from the ongoing Phase 2 COURAGE trial evaluating Regeneron's trevogrumab (anti-GDF8/anti-myostatin) with semaglutide (GLP-1 receptor agonist) with or without garetosmab (anti-activin A) for obesity.
The trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to the loss of lean mass.
Price Action: NVO stock is up 0.04% at $79.36 at the last check Wednesday.
Read Next:Photo by JHVEPhoto via Shutterstock
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga?
NOVO NORDISK (NVO): Free Stock Analysis Report
This article Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Why IONQ, RGTI and QBTS are Worth the Risk in Quantum Computing
Quantum computing stocks are high-risk, high-reward plays, where the tech still feels futuristic, but the potential upside could be transformative for your portfolio. While giants like NVIDIA (NVDA) and Alphabet (GOOGL) have stakes in the field, pure-play names like IonQ (IONQ), Rigetti Computing (RGTI), and D-Wave Quantum (QBTS) are gaining serious traction. Confident Investing Starts Here: Each is taking a distinct approach in a sector expected to grow significantly over the next decade. With quantum tech reaching what Nvidia's Jensen Huang recently called an 'inflection point,' these companies are riding a powerful wave of both investor excitement and tangible technological progress. IonQ (NYSE:IONQ) | The Trapped-Ion Powerhouse IonQ is shaping up to be the quarterback of the quantum computing world—everyone's watching, and for good reason. Their trapped-ion technology, which uses charged atoms suspended in electromagnetic fields, produces qubits with exceptional coherence times, translating to more stable and reliable calculations. They've already surpassed 100 qubits, and their systems are available across Amazon (AMZN), Microsoft (MSFT), and Google Cloud, making IonQ a top choice for developers building quantum applications. In Q1, IonQ posted $7.6 million in revenue and forecasted full-year revenue between $75–$95 million, nearly doubling last year's figure, while trimming losses to $0.14 per share from $0.19. The buzz lately? Their aggressive M&A strategy. IonQ recently acquired Lightsynq Technologies to accelerate the development of fault-tolerant quantum systems and invested $1 billion in Oxford Ionics to boost R&D, aiming to scale up to 2 million physical qubits by 2030. They've also forged partnerships with heavyweights such as AstraZeneca and Nvidia in quantum-powered drug discovery and secured a key contract under DARPA's Quantum Benchmarking Initiative. Yes, a $10.4 billion market cap is steep given current revenues, but the long-term thesis hinges on IonQ's strategic partnerships, cloud integration, and early mover advantage potentially paying off for investors willing to ride out the volatility. Is IonQ a Buy, Hold, or Sell? Currently, most analysts are bullish on IONQ stock. The stock features a Strong Buy consensus rating based on four Buy and one Hold ratings assigned in the past three months. No analyst rates the stock a sell. IONQ's average stock price target of $43 implies ~11% upside over the next twelve months, despite shares having already rallied about 400% since this time last year. Rigetti Computing (NASDAQ:RGTI) | The Superconducting Maverick Rigetti's story is a bit more turbulent, but still intriguing. Their superconducting gate-based systems are built for speed, executing operations in just 60–80 nanoseconds, far faster than ion-based platforms. That kind of performance is ideal for time-sensitive workloads, such as financial modeling and AI. As a vertically integrated company, Rigetti controls everything from chip design to cloud access, positioning itself for potential large-scale growth. Their 84-qubit Ankaa-3 system debuted in Q1, and they're targeting enterprise clients, including HSBC and Moody's. However, the financial picture is rough. Q1 revenue dropped 52% to $1.47 million, and the company reported a staggering $200.99 million net loss on just $10.79 million in revenue for 2023, highlighting a steep burn rate. Still, Rigetti isn't standing still. They landed a $35 million deal with Quanta Computer, secured a £3.5 million UK consortium lead focused on quantum error correction, and earned DARPA support—solid wins that keep them relevant. Looking ahead, analysts expect revenue to grow to $23 million in 2026 and $38 million in 2027. It's a high-risk play, but if execution improves, Rigetti could be at the start of a long-term turnaround. Is Rigetti Stock a Good Buy? On Wall Street, Rigetti stock carries a Strong Buy consensus rating based on five unanimous Buy ratings. No analyst rates the stock a hold or a sell. RGTI's average stock price target of $15 implies almost 24% upside potential over the next twelve months. D-Wave Quantum (NYSE:QBTS) | The Tempered All-Star D-Wave Quantum is taking a different path—and making no apologies for it. Their quantum annealing technology, designed for optimization tasks like supply chain logistics and drug discovery, is already producing real-world results. Their Advantage2 system, with over 4,400 qubits, recently completed a magnetic simulation in minutes—something a classical supercomputer would take a million years to solve, according to a Science journal paper. In Q1, revenue hit a record $15 million, a sixfold increase year-over-year, with strong momentum expected to continue. The stock has been on a tear, skyrocketing 1,281% over the past year, far outpacing IonQ's 402% and Rigetti's 840%. Their Leap cloud platform is available in 40+ countries and serves 25 Forbes Global 2000 clients, showcasing real commercial traction for quantum. But with a $5.22 billion market cap and a price-to-sales ratio nearing 200x, the valuation is steep and heavily speculative. The key question is whether D-Wave's annealing approach can hold its edge as gate-based systems advance. It's still early days, and the verdict remains uncertain—but for now, D-Wave is proving that practical quantum solutions might not be as far off as once thought. Is D-Wave a Good Stock to Buy? D-Wave is currently covered by six Wall Street analysts, all of whom hold a bullish outlook. The stock carries a Strong Buy consensus rating with all six analysts assigning a Buy rating over the past three months. However, QBTS's average price target of $13 suggests approximately 18% downside potential over the next twelve months. Why Roll the Dice? Quantum computing stocks are far from safe bets—they come with deep losses, sky-high valuations, and intense competition from tech giants like Google and IBM. Still, IonQ's enterprise-ready systems, Rigetti's speed-focused tech, and D-Wave's real-world traction make them standout players in a field with extensive long-term commercialization capacity. While the future of their revenues and profitability remains uncertain, all three deserve a spot on investor watchlists.
Yahoo
2 hours ago
- Yahoo
Bloom Energy's (BE) Alternative Power Play: UBS Sees Growth Ahead
Bloom Energy Corporation (NYSE:) is one of the . On June 12, UBS analyst Manav Gupta reiterated a 'Buy' rating on the stock with a $29.00 price target. The firm has reaffirmed its positive stance on the company while making minor adjustments to its quarterly estimates. It expects Bloom to report second-quarter 2025 sales of $365 million, an increase from the $326 million reported in the first quarter of 2025. It also expects improved profitability with second-quarter EBITDA forecasted to reach $35 million, up from $25 million in the previous quarter. A panoramic aerial view of a modern data center with high-performance computing. The firm projected that Bloom Energy will achieve total sales of $1,777 million for the full fiscal year 2025. All in all, the firm is bullish on the stock as Bloom continues to grow its presence in the alternative energy sector with its solid oxide fuel cell technology. Bloom Energy Corporation (NYSE:BE) develops solid-oxide fuel cell systems for on-site power generation, helping meet the growing energy demands of AI data centers. While we acknowledge the potential of BE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
Yahoo
6 hours ago
- Yahoo
Venture Global (VG) Extends Rally on $28-B LNG Facility
We recently published a list of . In this article, we are going to take a look at where Venture Global, Inc. (NYSE:VG) stands against other top-performing companies on Tuesday. Venture Global rallied by 8.37 percent on Tuesday to end at $17.04 apiece as investors resumed bargain-hunting following the commencement of its $28 billion liquefied natural gas (LNG) facility in Louisiana. Called the CP2 LNG, the facility will sit on a 1,150-acre site in Cameron Parish and is expected to be able to export at least 20 million tons of LNG per annum. According to the company, the new facility is also expected to generate 10,500 jobs, of which 7,500 will start during the construction, and 3,000 upon commercial operations. It is also expected to pay more than $4 billion in local property taxes once the LNG comes into full swing. A deep sea tanker vessel laden with liquified natural gas, contrailing a majestic stream of white smoke. Venture Global, Inc. (NYSE:VG) said it targets to kick off commercial operations in 2027. The facility is expected to make Venture Global, Inc. (NYSE:VG) the largest LNG exporter in the US, and the second largest in the world. Overall, VG ranks 2nd on our list of top-performing companies on Tuesday. While we acknowledge the potential of VG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
